参考文献/References:
[1].Guha K,McDonagh T. Heart failure epidemiology:European perspective[J]. Curr Cardiol Rev,2013,9:123-127.
[2].Braunwald E. Heart failure[J]. JACC Heart Fail,2013,1:1-20.
[3].Fujita S,Shimojo N,Terasaki F,et al. Atrial natriuretic peptide exerts protective action against angiotensin Ⅱ induced cardiac remodeling by attenuating inflammation via endothelin-1 endothelin receptor a cascade[J]. Heart Vessels,2013,28(5):646-657.
[4].[4]Hausfater P,Claessens YE,Martinage A,et al. Prognostic value of PCT,copeptin, MR-proADM,MR-proANP and CT-proET-1 for severe acute dyspnea in the emergency department: the BIODINER study[J]. Biomarkers,2017,22(1):28-34.
[5].[5]Cui K, Huang W, Fan JQ, et al. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction[J]. Medicine(Baltimore),2018,97(36):e12277.
[6].[6]Darche FF, Baumg?rtner C, Biener M,et al. Comparative accuracy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients[J]. ESC Heart Fail,2017,4:232-240.
[7].[7]Xu X,Li Z,Gao W,et al. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside[J]. Biomarkers,2011,16(6):466-475.
[8].[8]Liu JX,Li YP,Liu BH,et al. Repeated measurement of growth-differentiation factor-15 in Chinese Han patients with post-myocardial infarction chronic heart failure[J]. J Geriatr Cardiol,2018,15(10):618-627.
[9].[9]Li J, Cui YM, Huang AA, et al.Additional diagnostic value of growth differentiation factor-15(GDF-15) to N-Terminal B-type natriuretic peptide(NT-proBNP) in patients with different stages of heart failure[J]. Med Sci Monit,2018,24:4992-4999.
[10].[10]Fluschnik N, Ojeda F, Zeller T, et al. Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease[J]. PLoS One,2018,13(5):e0197497.
[11].[11]Salio M,Chimenti S,de Angelis N,et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarctoni[J].Circulation,2008,117:1055-1064
[12].[12]Nerkiz P,Doganer YC,Aydogan U,et al. Serum pentraxin-3 level in patients who underwent coronary angiography and relationship with coronary atherosclerosis[J]. Med Princ Pract,2015,24(4):369-375.
[13].[13]Tomandlova M, Jarkovsky J, Tomandl J, et al. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress[J]. Dis Mark,2015,2015:159051.
[14].[14]Matsubara J, Sugiyama S, Nozaki T, et al.Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction[J].J Am Heart Assoc,2014,3(4):e000928.
[15].[15]Liu H, Guo X, Yao K, et al. Pentraxin-3 predicts long-term cardiac events in patients with chronic heart failure[J]. Biomed Res Int,2015,2015:817615.
[16].[16]Li LL,Peng C,Zhang ML,et al. Mesenchymal stem cells overexpressing adrenomedullin improve heart function through antifibrotic action in rats experiencing heart failure[J]. Mol Med Rep,2018,17:1437-1444.
[17].[17]Falkentoft AC,R?rth R, Iversen K, et al. MR-proADM as a prognostic marker in patients with ST-segment-elevation myocardial infarction—DANAMI-3(a Danish Study of Optimal Acute Treatment of Patients With STEMI)substudy[J].J Am Heart Assoc,2018,7(11):e008123.
[18].[18]Lassus J,Gayat E,Mueller C,et al.Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure:the Multinational Observational Cohort on Acute Heart Failure (MOCA) study[J].Int J Cardiol,2013,168:2186-2194.
[19].[19]Li X,Chan TO,Myers V,et al. Controlled and cardiac-restricted overexpression of the arginine vasopressin v1a receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling[J]. Circulation, 2011,124(5):572-581.
[20].[20]Yan JJ,Lu Y,Kuai ZP,et al. Predictive value of plasma copeptin level for the risk and mortality of heart failure:a meta-analysis[J]. J Cell Mol Med,2017,21(9):1815-1825.
[21].[21]Düngen HD,Tscholl V,Obradovic D,et al. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure:results from the MOLITOR study[J].ESC Heart Fail,2018,5(2):288-296.
[22].[22]Jia J,Chang GL,Qin S,et al. Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure,and prediction of adverse events in a 90-day follow-up period:a prospective clinical observation trial[J]. Exp and Ther Med,2017,13:1554-1560.
[23].[23]Xu L,Liu XM,Wu S,et al. The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction:a cross-sectional study[J]. Medicine,2018,97:39.
[24].[24]Winther JA,Brynildsen J,H?iseth AD,et al. Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure:data from the ACE 2 study[J]. Respir Res,2017,18(1):184.
[25].[25]Demyanets S,Kaun C,Pentz R,et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J]. J Mol Cell Cardiol,2013,60:16-26.
[26].[26]Jenkins WS,Roger VL,Jaffe AS,et al. Prognostic value of soluble ST2 after myocardial infarction:a community perspective[J]. Am J Med,2017,130(9): 1112.e9-1112.e15.
[27].[27]Januzzi JL Jr,Peacock WF,Maisel AS,et al. Measurement?of the?interleukin?family?member?ST2?in?patients?with?acute?dyspnea:results?from the?PRIDE(Pro-Brain?Natriuretic?Peptide?Investigation?of?Dyspnea?in the?Emergency?Department)?study[J]. J Am Coll Cardiol,2007,50(7):607-613.
[28].[28]Whellan DJ,O’Connor CM,Lee KL,et al. Heart failure and a controlled trial investigating outcomes of exercise training(HF-ACTION):design and rationale[J]. Am Heart J,2007,153(2):201-211。
[29].[29]AbouEzzeddine OF, McKie PM, Dunlay SM,et al.Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction[J].J Am Heart Assoc,2017,6(2):e004382.
[30].[30]Zile MR,Jhund PS,Baicu CF,et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study[J]. Circ Heart Fail,2016,9(1):e002551。
[31].[31]Yancy CW ,Jessup M ,Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Am Coll Cardiol,2017,70(6):776-803.
[32].[32]Sharma UC,Pokharel S,van Brakel TJ,et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J] .Circulation,2004,110(19):3121-3128.
[33].[33]Cui YM, Qi X, Huang AA, et al. Differential and predictive value of galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction[J]. Med Sci Monit,2018,24:5139-5146.
[34].[34]French B, Wang L, Ky B, et al. Prognostic value of galectin-3 for adverse outcomes in chronic heart failure[J]. J Cardb Fail,2016,22(4):256-262.
[35].[35]AbouEzzeddine OF, Haines P, Stevens S, et al. Galectin-3 in heart failure with preserved ejection fraction:a relax trial substudy[J]. JACC Heart Fail,2015,3(3):245-252.
相似文献/References:
[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial
Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[3]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(1):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[4]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(1):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[5]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(1):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[6]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(1):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[7]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(1):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[8]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[9]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[10]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[11]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(1):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[12]孙悦宁 富路.左心室逆重构在心力衰竭中的研究新进展[J].心血管病学进展,2021,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]
SUN Yuening,FU Lu.Research Progress of Left Ventricular Reverse Remodeling in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(1):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]
[13]魏天天?王学超?吴海波?杜荣品.心力衰竭生物标志物的研究进展[J].心血管病学进展,2021,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.009]
WEI Tiantian,WANG Xuechao,WU Haibo,et al.Biomarkers of Heart Failure[J].Advances in Cardiovascular Diseases,2021,(1):610.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.009]